Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|GOG-0204||GOG||A Randomized Phase III Trial of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin in Stage IVB; Recurrent; or Persistent Carcinoma of the Cervix||Adult CIRB - Late Phase Emphasis||Completed|
|S0777||SWOG||A Randomized Phase III Trial of CC-5013 (Lenalidomide; NSC-703813) and Low Dose Dexamethasone (LLD) Versus Bortezomib (PS-341; NSC-681239); Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction; in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA5191||ECOG-ACRIN||A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1505||SWOG||A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1616||SWOG||A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent||Adult CIRB - Late Phase Emphasis||Available to Open|
|EAA173||ECOG-ACRIN||Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NCCTG-N06C6||NCCTG||A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|S0200||SWOG||A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy||Adult CIRB - Late Phase Emphasis||Completed|
|CALGB-40302||CALGB||Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized; Double-Blind; Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E4A08||ECOG||A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib; Melphalan; and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation||Adult CIRB - Late Phase Emphasis||Completed|